Your browser doesn't support javascript.
loading
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo.
Nixon, Christopher C; Mavigner, Maud; Sampey, Gavin C; Brooks, Alyssa D; Spagnuolo, Rae Ann; Irlbeck, David M; Mattingly, Cameron; Ho, Phong T; Schoof, Nils; Cammon, Corinne G; Tharp, Greg K; Kanke, Matthew; Wang, Zhang; Cleary, Rachel A; Upadhyay, Amit A; De, Chandrav; Wills, Saintedym R; Falcinelli, Shane D; Galardi, Cristin; Walum, Hasse; Schramm, Nathaniel J; Deutsch, Jennifer; Lifson, Jeffrey D; Fennessey, Christine M; Keele, Brandon F; Jean, Sherrie; Maguire, Sean; Liao, Baolin; Browne, Edward P; Ferris, Robert G; Brehm, Jessica H; Favre, David; Vanderford, Thomas H; Bosinger, Steven E; Jones, Corbin D; Routy, Jean-Pierre; Archin, Nancie M; Margolis, David M; Wahl, Angela; Dunham, Richard M; Silvestri, Guido; Chahroudi, Ann; Garcia, J Victor.
Afiliação
  • Nixon CC; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Mavigner M; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Sampey GC; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Brooks AD; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • Spagnuolo RA; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Irlbeck DM; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Mattingly C; UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ho PT; Qura Therapeutics, Chapel Hill, NC, USA.
  • Schoof N; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • Cammon CG; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Tharp GK; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Kanke M; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wang Z; Qura Therapeutics, Chapel Hill, NC, USA.
  • Cleary RA; HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.
  • Upadhyay AA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • De C; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wills SR; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Falcinelli SD; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Galardi C; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
  • Walum H; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Schramm NJ; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Deutsch J; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Lifson JD; Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
  • Fennessey CM; Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Keele BF; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Jean S; GlaxoSmithKline Research and Development, Collegeville, PA, USA.
  • Maguire S; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Liao B; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Browne EP; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Ferris RG; Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
  • Brehm JH; International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Favre D; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Vanderford TH; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Bosinger SE; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Jones CD; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Routy JP; UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Archin NM; Qura Therapeutics, Chapel Hill, NC, USA.
  • Margolis DM; Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Wahl A; Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Dunham RM; UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Silvestri G; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Chahroudi A; Qura Therapeutics, Chapel Hill, NC, USA.
  • Garcia JV; HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.
Nature ; 578(7793): 160-165, 2020 02.
Article em En | MEDLINE | ID: mdl-31969707
ABSTRACT
Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy (ART). Estimates indicate that more than 70 years of continuous, fully suppressive ART are needed to eliminate the HIV reservoir1. Alternatively, induction of HIV from its latent state could accelerate the decrease in the reservoir, thus reducing the time to eradication. Previous attempts to reactivate latent HIV in preclinical animal models and in clinical trials have measured HIV induction in the peripheral blood with minimal focus on tissue reservoirs and have had limited effect2-9. Here we show that activation of the non-canonical NF-κB signalling pathway by AZD5582 results in the induction of HIV and SIV RNA expression in the blood and tissues of ART-suppressed bone-marrow-liver-thymus (BLT) humanized mice and rhesus macaques infected with HIV and SIV, respectively. Analysis of resting CD4+ T cells from tissues after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and robust induction of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, thymus, bone marrow, liver and lung. This promising approach to latency reversal-in combination with appropriate tools for systemic clearance of persistent HIV infection-greatly increases opportunities for HIV eradication.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / NF-kappa B / Síndrome de Imunodeficiência Adquirida dos Símios / HIV-1 / Vírus da Imunodeficiência Símia / Latência Viral Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / NF-kappa B / Síndrome de Imunodeficiência Adquirida dos Símios / HIV-1 / Vírus da Imunodeficiência Símia / Latência Viral Idioma: En Ano de publicação: 2020 Tipo de documento: Article